You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
20 November 2020
Johnson & Johnson’s Benacort Hayfever Relief – containing the intranasal corticosteroid budesonide – has been switched to general-sales list (GSL) status in the UK.
16 October 2020
Johnson & Johnson’s (J&J’s) OTC business reported strong sales growth in the US in the third quarter of 2020 but international sales experienced a significant fall.
28 September 2020
Johnson & Johnson’s (J&J’s) Consumer Health division is investing USD800 million between now and 2030 to “make its products more sustainable for a healthier planet”.
20 July 2020
Johnson & Johnson’s (J&J’s) OTC sales in the US increased by almost a third in the second quarter of 2020 amid the COVID-19 pandemic. However, the US-based company’s international OTC sales dropped by 5.0% on an operational basis.
21 May 2020
Johnson & Johnson (J&J) Consumer Health has discontinued talc-based Johnson’s Baby Powder in the US and Canada, but will continue selling the product in other markets around the world.
12 May 2020
Sweden’s Karo Pharma has acquired the remaining European rights to the Pevaryl antifungal brand portfolio from Johnson & Johnson (J&J) for EUR58 million (USD63 million).
16 April 2020
Johnson & Johnson’s (J&J’s) OTC sales in the US increased by more than a third in the first quarter of 2020 amid the COVID-19 pandemic. Chairman and chief executive officer Alex Gorsky said the company had increased and refocused production of Tylenol (acetaminophen).
23 January 2020
Johnson & Johnson (J&J) has announced plans to “rationalise” the product portfolio of its Consumer division. The news came as the division reported worldwide sales up by 2.1% on an operational basis in the fourth quarter of 2019.